FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:298-300 January 20, 2005 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Developing a preventive human immunodeficiency virus type 1 (HIV-1) vaccine that decisively reduces the rate of spread of the AIDS pandemic will take many years, at best. In the meantime, can the scientific community apply other biology-based methods to halt the transmission of HIV-1? A recent study performed by Lederman and colleagues with the use of a nonhuman primate model of sexual transmission indicates that this feat may be possible.¹ By applying a specific inhibitor of virus–cell fusion to the vaginal vault of rhesus macaques, Lederman et al. protected the animals against a subsequent challenge by a vaginally inoculated, genetically . . . [Full Text of this Article]

Source Information

From the Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York.

This article has been cited by other articles:

• Gaertner, H., Cerini, F., Escola, J.-M., Kuenzi, G., Melotti, A., Offord, R., Rossitto-Borlat, I., Nedellec, R., Salkowitz, J., Gorochov, G., Mosier, D., Hartley, O. (2008). Highly potent, fully recombinant anti-HIV chemokines: Reengineering a low-cost microbicide. Proc. Natl. Acad. Sci. USA 105: 17706-17711 [Abstract] [Full Text]  
• Isaacs, C. E., Rohan, L., Xu, W., Jia, J. H., Mietzner, T., Hillier, S. (2006). Inactivation of Herpes Simplex Virus Clinical Isolates by Using a Combination Microbicide. Antimicrob. Agents Chemother. 50: 1063-1066 [Abstract] [Full Text]